Side-by-side · Research reference
5-Amino-1MQvsBronchogen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongAUTO-DRAFTED8/38 cited
BAnimal-StrongHUMAN-REVIEWED16/35 cited
5-Amino-1MQ
NNMT inhibitor · Methylation / SAM modulation
Oral · Once daily fasted
Bronchogen
Tetrapeptide Bioregulator · Khavinson-School
Research models: tissue culture / parenteral
01Mechanism of Action
Parameter
5-Amino-1MQ
Bronchogen
Primary target
Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018
Bronchial epithelial cellsKuzubova 2015
Pathway
NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018
Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration
Downstream effect
Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018
Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B productionKuzubova 2015Titova 2017
Feedback intact?
—
—
Origin
Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018
Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework
Antibody development
—
—
02Dosage Protocols
Parameter
5-Amino-1MQ
Bronchogen
Frequency
Once daily, fasted
—
Lower / starter dose
50 mg / day
—
Evidence basis
Animal-strong; no human RCT dataNeelakantan 2018
Animal models (rat) / organotypic cultureTitova 2017Kuzubova 2015Zakutskiĭ 2006
No human clinical trials reported in available literature.
Duration
8–12 weeks per cycle
—
Form
Oral capsule
—
Timing
Morning fasted preferred
—
Half-life
Hours (estimated; no human PK published)
—
Effective concentration (culture)
—
0.05 ng/mLZakutskiĭ 2006
Demonstrated in organotypic tissue culture of bronchial explants.
Treatment duration (animal)
—
1 month (30 days)Kuzubova 2015Titova 2017
Course duration in rat COPD models.
Tissue specificity
—
Selective for bronchopulmonary tissue
Part of Khavinson organ-specific bioregulator series.
04Side Effects & Safety
Parameter
5-Amino-1MQ
Bronchogen
GI symptoms
Mild nausea (anecdotal)
—
Methylation disruption
Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)
—
Long-term safety
Unknown — no human trials
—
Cancer risk
Unclear — NNMT also studied in oncology contexts
—
Pregnancy / OB
Avoid
—
Drug interactions
Theoretical with niacin / B-vitamin supplements
—
Animal safety profile
—
No adverse effects reported in published rat studies
Limited safety data; only animal models available.
Human data
—
Absent — no clinical trials in humans reported
Long-term effects
—
Unknown — maximum study duration 30 days in animals
Absolute Contraindications
5-Amino-1MQ
- ·Pregnancy / breastfeeding
- ·Active malignancy
Bronchogen
—Relative Contraindications
5-Amino-1MQ
- ·Methylation-sensitive conditions (MTHFR mutation)
- ·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)
Bronchogen
—05Administration Protocol
Parameter
5-Amino-1MQ
Bronchogen
1. Form
Oral capsule. No injection.
Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.
2. Administration
Take with water, fasted preferred.
In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts.Titova 2017Kuzubova 2015
3. Timing
Morning fasted.
Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation.Zakutskiĭ 2006
4. Storage
Room temp ≤25 °C, dry place.
Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.
5. Caveat
Monitor B-vitamin status with chronic use.
—